The Efficacy of Lambrolizumab in Advanced Melanoma
Antoni Ribas, MD, PhD, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.
Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.
Clinical Pearls
Researchers have seen clinically meaningful activity in a substantial number of patients, Ribas says. In the trial, the overall response rate was 38% and 90% of patients experienced durable response. Ribas notes that adverse events in the trial were minimal.
- Clinically meaningful activity was observed in the trial
- The overall response rate was 38%, pooled across all doses and schedules and including both ipilimumab-naive and ipilimumab-pretreated patients
- Preliminary data suggest that lambrolizumab has significant antitumor activity and is well tolerated with manageable side effects in both ipilimumab-naive and ipilimumab-pretreated patients with melanoma
<<<
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
